Our discovery of the connection between persistent stress granules and neurodegenerative disease is one of the most promising developments today and could offer amazing new hope for patients and their families. This potential breakthrough is especially significant after years of disappointment in ALS and Alzheimer’s research. 

The strength of our science is the result of a long commitment to neurodegenerative research, exacting standards and a fresh, out-of-the-box approach. We have been awarded four peer-reviewed grants and support from major pharmaceutical companies. 

We have assembled an elite team of award-winning scientists and experienced drug developers to help ensure success in overcoming the challenge of ALS (amyotrophic lateral sclerosis, better known as Lou Gehrig’s disease), Alzheimer’s (AD) and other neurodegenerative diseases. 

Although neurodegenerative drug development has historically been associated with some level of risk, our team has made great strides in mitigating this problem. We have established a proven genetic cause, a validated pathology, initial proof of concept and have assembled an experienced team to make it happen.